305 related articles for article (PubMed ID: 12531809)
1. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
[TBL] [Abstract][Full Text] [Related]
2. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
3. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
Tolar J; Bostrom BC; La MK; Sather HN
Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
[TBL] [Abstract][Full Text] [Related]
4. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
Nagatoshi Y; Matsuzaki A; Suminoe A; Inada H; Ueda K; Kawakami K; Yanai F; Nakayama H; Moritake H; Itonaga N; Hotta N; Fujita K; Hidaka Y; Yamanaka T; Kawano Y; Okamura J
Pediatr Blood Cancer; 2010 Aug; 55(2):239-47. PubMed ID: 20582970
[TBL] [Abstract][Full Text] [Related]
8. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K
Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968
[TBL] [Abstract][Full Text] [Related]
9. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
Chauvenet AR; Martin PL; Devidas M; Linda SB; Bell BA; Kurtzberg J; Pullen J; Pettenati MJ; Carroll AJ; Shuster JJ; Camitta B
Blood; 2007 Aug; 110(4):1105-11. PubMed ID: 17442849
[TBL] [Abstract][Full Text] [Related]
10. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.
Winick N; Martin PL; Devidas M; Shuster J; Borowitz MJ; Paul Bowman W; Larsen E; Pullen J; Carroll A; Willman C; Hunger SP; Carroll WL; Camitta BM
Leukemia; 2020 Apr; 34(4):1006-1016. PubMed ID: 31728054
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
12. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
Waber DP; Carpentieri SC; Klar N; Silverman LB; Schwenn M; Hurwitz CA; Mullenix PJ; Tarbell NJ; Sallan SE
J Pediatr Hematol Oncol; 2000; 22(3):206-13. PubMed ID: 10864051
[TBL] [Abstract][Full Text] [Related]
13. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.
Bonilla M; Moreno N; Marina N; deReyes G; Shurtleff SA; Downing JR; Behm FG; Harrison PL; Ribeiro RC; Peña O; Crist WM; Antillon FG
J Pediatr Hematol Oncol; 2000; 22(6):495-501. PubMed ID: 11132215
[TBL] [Abstract][Full Text] [Related]
14. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
[TBL] [Abstract][Full Text] [Related]
15. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Matloub Y; Bostrom BC; Hunger SP; Stork LC; Angiolillo A; Sather H; La M; Gastier-Foster JM; Heerema NA; Sailer S; Buckley PJ; Thomson B; Cole C; Nachman JB; Reaman G; Winick N; Carroll WL; Devidas M; Gaynon PS
Blood; 2011 Jul; 118(2):243-51. PubMed ID: 21562038
[TBL] [Abstract][Full Text] [Related]
16. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
17. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
18. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
[TBL] [Abstract][Full Text] [Related]
19. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
[TBL] [Abstract][Full Text] [Related]
20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
